In addition, patients with DLBCL with higher levels of BCL6 mRNA and protein levels show a better prognosis as compared with those with lower levels (7) supporting the role of BCL6 in the biology of subtypes of DLBCL and suggesting that BCL6 expression is associated with higher response rates to current chemoimmunotherapy. Here, BCL6 is linked to diffuse large B-cell lymphoma.